Edwards Lifesciences (NYSE: EW) is expected to report Q3 earnings on Oct. 19. Here's what Wall Street wants to see:

The 10-second takeaway
 Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Edwards Lifesciences's revenues will expand 8.6% and EPS will expand 47.4%.

The average estimate for revenue is $448.2 million. On the bottom line, the average EPS estimate is $0.56.

Revenue details
 Last quarter, Edwards Lifesciences reported revenue of $482.0 million. GAAP reported sales were 12% higher than the prior-year quarter's $431.2 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
 Last quarter, non-GAAP EPS came in at $0.67. GAAP EPS of $0.57 for Q2 were 19% higher than the prior-year quarter's $0.48 per share.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Recent performance
 For the preceding quarter, gross margin was 73.1%, 270 basis points better than the prior-year quarter. Operating margin was 19.9%, 240 basis points better than the prior-year quarter. Net margin was 14.1%, 60 basis points better than the prior-year quarter.

Looking ahead

The full year's average estimate for revenue is $1.89 billion. The average EPS estimate is $2.56.

Investor sentiment
 The stock has a three-star rating (out of five) at Motley Fool CAPS, with 146 members out of 200 rating the stock outperform, and 54 members rating it underperform. Among 62 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 41 give Edwards Lifesciences a green thumbs-up, and 21 give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Edwards Lifesciences is outperform, with an average price target of $97.11.